Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7808-7816

  Chao, Qi ^a   Sprankle, Kelly G ^a   Grotzfeld, Robert M ^a   Lai, Andiliy G ^a   Carter, Todd A ^a   Velasco, Anne Marie ^a   Gunawardane, Ruwanthi N ^a   Cramer, Merryl D ^a   Gardner, Michael F ^a   James, Joyce ^a   Zarrinkar, Patrick P ^a   Patel, Hitesh K ^a   Bhagwat, Shripad S ^a  

^a Ambit Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CD135 ANTIGEN; ENZYME INHIBITOR; FMS LIKE TYROSINE KINASE 3 INHIBITOR; N (5 TERT BUTYL ISOXAZOL 3 YL) N' [4 [7 (2 MORPHOLIN 4 YL ETHOXY)IMIDAZO[2,1 B][1,3]BENZOTHIAZOL 2 YL]PHENYL]UREA DIHYDROCHLORIDE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; WATER;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; RAT; RODENT; SOLUBILITY; TUMOR; TUMOR XENOGRAFT;

ANIMALS; BENZOTHIAZOLES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; MALE; MICE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RATS; SOLUBILITY; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72249087752     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9007533     Document Type: Article

References (21)

1. Drexler, H. G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996, 10, 588-599. (Pubitemid 26144436)
2. Gilliland, D. G.; Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100, 1532-1542.
3. Heinrich, M. C. Targeting FLT3 Kinase in Acute Myeloginous Leukemia: Progress, Perils, and Prospects. Mini-Rev. Med. Chem. 2004, 4, 255-271.
4. Levis, M.; Small, D. FLT3 Tyrosine Kinase Inhibitors. Int. J. Hematol. 2005, 82, 100-107.
5. Schmidt-Arras, D.; Schwable, J.; Bohmer, F. D.; Serve, H. FLT3 Receptor Tyrosine Kinase as a Drug Target in Leukemia. Curr. Pharm. Des. 2004, 16, 1867-1883.
6. Zhang, W.; Konopleva, M.; Shi, Y. X.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintas-Cardama, A.; Small, D.; Cortes, J.; Andreef, M. Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. J. Natl. Cancer Inst. 2008, 100, 184-198.
7. Pratz, K. W.; Cortes, J.; Roboz, G. J.; Rao, N.; Arowojolu, O.; Stine, A.; Shiotsu, Y.; Shudo, A.; Akinaga, S.; Smmal, D.; Karp, J. E.; Levis, M. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009, 113, 3938-3946.
8. Whartenby, K. A.; Calabresi, P. A.; McCadden, E.; Nguyen, B.; Kardian, B.; Wang, T.; Mosse, T.; Pardoll, D. M.; Small, D. Inhibition of FLT3 targets DCs to ameliorate autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 16741-16746.
9. Whartenby, K. A.; Small, D.; Calabresi, P. A. FLT3 inhibitors for the treatment of autoimmune disease. Expert Opin. Invest. Drugs 2008, 17, 1685-1692.
10. Patel, H. K.; Grotzfeld, R. M.; Lai, A. G.; Mehta, S. A.; Milanov, Z. V.; Chao, Q.; Sprankle, K. G.; Carter, T. A.; Velasco, A. M.; Fabian, M. A.; James, J.; Treiber, D. T.; Lockhart, D. J.; Zarrinkar, P. P.; Bhagwat, S. S. Arylcarboxyamino-Substituted Diaryl Ureas as Potent and Selective FLT3 Inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 5182-5185.
11. Grin, N. P.; Krasovskii, A. N.; Kochergin, P. M. Investigations in the Imidazole Series. Chem. Heterocycl. Compd. 1972, 8, 1149-1152.
12. Kaye, I. A.; Burlant, W. J.; Price, L. Thiocyanation of p-Dialkylamino- alkoxyanilines. J. Org. Chem. 1951, 16, 1421-1426.
13. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M; Galvin, M.; Gerlack, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
14. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
15. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, L. M.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
16. Zarrinkar, P. P.; Gunawardane, R. N.; Cramer, M. D.; Gardner, M. F.; Brigham, D.; Belli, B.; Karaman, M. W.; Pratz, K. W.; Pallares, G.; Chao, Q.; Sprankle, K. G.; Patel, H. K.; Armstrong, R. C.; James, J.; Bhagwat, S. S. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia. Blood 2009, DOI 10.1182/blood-2009-05-222034.
17. Goldstein, D. M.; Gray, N. S.; Zarrinkar, P. P. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discovery 2008, 7, 1-7.
18. Bamborough, P.; Drewry, D.; Harper, G.; Schneider, K.; Smith, G. K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 2008, 51, 7898-7914.
19. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngain, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101, 3597-3605.
20. Cortes, J.; Foran, J. M.; Devettan, M. P.; Giles, F. J.; James, J.; Zarrinkar, P. P.; Silverman, M. H.; Kelly, K. A.; Padre, N. M.; Bhagwat, S. S.; Wierenga, W. Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor. Blood (ASH Annu. Meet. Abstr.) 2007, 110, 1597.
21. Cortes, J. E.; Ghirdaladze, D.; Foran, J. M.; DeVetten, M. P.; Zodelava, M.; Levis,M. J.; Padre, N. M.; James, J.; Zarrinkar, P. P; Corringham, R. Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor. Blood (ASH Annu. Meet. Abstr.) 2008, 112, 767.